Our Work
Latham Advises on Vor Bio’s Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of US$115.8 Million
December 7, 2022
Firm represents the underwriters and placement agents in a financing for the clinical-stage cell and genome engineering company.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately US$115.8 million. The offering and concurrent private placement are expected to close on December 9, 2022, subject to satisfaction of customary closing conditions.
Latham & Watkins LLP represents the underwriters and placements agents in the transactions with a corporate team led by partners Peter Handrinos and Nathan Ajiashvili, with associates Matt DeSilva, MacLane Taggart, and Alexandra Kustra.